The 2026 PCAC Peptide Vote

What happened

On 23–24 July 2026 the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed seven peptides nominated for the 503A Bulks List — the list of bulk substances U.S. pharmacies may use when compounding prescription preparations. Six were recommended for inclusion: BPC-157, KPV and TB-500 (each 8–6), MOTS-c (7–5), Semax (8–5) and Epitalon (7–5). The seventh, Emideltide — the international nonproprietary name of DSIP — was voted down 6–7, the only rejection of the session.

Every recommendation went against the written position of the FDA's own scientific reviewers, who had advised against listing all seven substances for lack of safety and efficacy evidence. Six times in a row the committee disagreed with the agency's staff; only on Emideltide did the two sides land in the same place.

The key word throughout is «recommended». An advisory committee advises; it does not decide. Nothing in U.S. law changed on 24 July 2026 — and as of this article's publication, nothing has changed since.

Who votes, and what the 503A list is

PCAC is a standing panel of outside experts — pharmacists, physicians, scientists — that advises the FDA on pharmacy compounding: medicines prepared for an individual patient on prescription, outside the industrial approval pipeline. Like every FDA advisory committee, it issues non-binding recommendations. The agency usually follows its committees, but it is not obliged to — and it has overruled them before.

Section 503A of the U.S. Food, Drug, and Cosmetic Act allows a pharmacy to compound with a bulk substance in three cases only: the substance has a USP/NF monograph, it is a component of an approved drug, or it appears on the 503A Bulks List. None of the seven peptides passes the first two tests — which is exactly why the list, and this vote, matter at all.

A place on the list would mean one narrow thing: pharmacies could lawfully use the substance in compounded prescriptions. It would not make the substance an approved medicine, would not certify that it works, and would not impose the manufacturing controls that approved drugs carry.

How the committee voted

BPC-157, KPV, TB-500 and MOTS-c were voted on 23 July; Semax, Epitalon and Emideltide on 24 July. The margins were narrow throughout — the committee held fifteen voting seats, no substance collected more than eight votes in favour, and several ballots recorded one or two abstentions.

The last column deserves a second look: the research status of every one of the seven is exactly what it was before the meeting. A committee's vote adds no clinical evidence — how we assign those statuses is described in How to Read Peptide Data.

What this does not mean

Most misreadings of this news live in the gap between «a committee recommended» and «it is now allowed». Four points close that gap.

• The vote binds no one. PCAC advises; the FDA decides. The agency can accept the recommendation, reject it or act on only part of it. An advisory vote is not an agency action.
• Even full agreement would change nothing overnight. The 503A Bulks List changes only through formal notice-and-comment rulemaking: a proposed rule, a public comment period, a final rule — a process that usually takes 8–12 months. It had not begun as of this article's publication, and until it ends pharmacies have no clear legal basis to compound these peptides.
• The 503A list is not drug approval. Listing governs which substances pharmacies may compound with on prescription. It says nothing about whether a substance is effective, and it carries none of the quality controls that approved, industrially manufactured medicines go through.
• The committee overruled the FDA's own reviewers six times in a row. Agency scientists had recommended against all seven peptides. That disagreement is now part of the record the FDA will weigh — and one more reason to treat the outcome as open rather than settled.

A recommendation is advice to the agency, not a new rule. The 503A list changes only through formal rulemaking — and that has not happened.

What changes for you

For now, practically nothing — and that is not an anticlimax, it is how the process is designed to work.

The research statuses of the seven peptides are unchanged, because the vote produced no new data about safety or effectiveness in humans. BPC-157 is still preclinical, six of the seven are still unapproved in every jurisdiction, and Semax's approval remains a local, Russian one. If the FDA eventually agrees with its committee and completes rulemaking, U.S. pharmacies will gain a lawful way to compound these substances on prescription. That would change access — not evidence.

If you follow the topic, the meaningful checkpoints are these:

• A proposed rule on the 503A list in the Federal Register — the FDA's first formal response to the vote.
• The final rule — only at that point does the list actually change.
• The «Regulatory status» sections of the seven profiles, which we update as the process moves: BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon, DSIP.

And if you want the habit of reading statuses, doses and evidence without overreading them, start with How to Read Peptide Data.

Sources

The facts above come from the official meeting record and from legal and medical-press analyses of it. All links were checked on 10 August 2026.

1. 01
   FDA — July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee

   the official meeting page: agenda, briefing documents and the uses evaluated for each substance.

2. 02
   Federal Register — Pharmacy Compounding Advisory Committee; Notice of Meeting

   the notice announcing the meeting, docket FDA-2025-N-6895.

3. 03
   Holland & Knight — FDA Advisory Committee Endorses Compounding of Certain Peptides

   legal analysis: six endorsements, one rejection, and why none of it binds the agency.

4. 04
   Mintz — FDA's Advisory Committee Votes on Peptides: What It Does and Doesn't Do

   what the vote changes and what it does not, including the reviewers' position.

5. 05
   Buchanan Ingersoll & Rooney — PCAC Recommends Six Peptides for the 503A Bulks List

   what the recommendation means for compounding pharmacies.

6. 06
   Medical Daily — FDA Panel Ends Peptide Review Backing Six of Seven

   the vote tallies, abstentions and quotes from committee members.

7. 07
   ABC News — FDA advisory committee votes to add popular peptide BPC-157

   mainstream coverage of the BPC-157 vote.